J05A ART unspecified J05A-BEV Bevirimat J05A-PBT Participant in Blinded Trial J05AE PI unspecified J05AE-MOZ Mozenavir (DMP-450) J05AE01 Saquinavir (gel, not specified) J05AE01-SQH Saquinavir hard gel (INVIRASE) J05AE01-SQS Saquinavir soft gel (FORTOVASE) J05AE02 Indinavir (CRIXIVAN) J05AE03 Ritonavir (NORVIR) J05AE03-H Ritonavir high dose (NORVIR) J05AE03-L Ritonavir low dose (NORVIR) J05AE04 Nelfinavir (VIRACEPT) J05AE05 Amprenavir (AGENERASE) J05AE07 Fos-amprenavir (Telzir, Lexiva) J05AE08 Atazanavir (Reyataz) J05AE09 Tipranavir (Aptivus) J05AE10 Darunavir (TMC-114, Prezista) J05AF NRTI unspecified J05AF-ALO Alovudine J05AF-AMD Amdoxovir (DADP) J05AF-FOZ Fozivudine tidoxi J05AF-LDN Lodenosine (trialdrug) J05AF-RVT Reverset J05AF01 Zidovudine (AZT, RETROVIR) J05AF02 Didanosine (ddI) (VIDEX) J05AF03 Zalcitabine (ddC) (HIVID) J05AF04 Stavudine (d4T) (ZERIT) J05AF05 Lamivudine (3TC, EPIVIR) J05AF06 Abacavir (1592U89) (ZIAGEN) J05AF07 Tenofovir (VIREAD) J05AF09 Emtricitabine J05AF13 TAF: Tenofoviralafenamid (TAF) J05AG NNRTI unspecified J05AG-CPV Capravirine J05AG-DPC083 DPC 083 J05AG-DPC961 DPC 961 J05AG-EMV Emivirine (MKC442) J05AG-LOV Loviride J05AG01 Nevirapine (VIRAMUN) J05AG02 Delavirdine (U-90152) (RESCRIPTOR) J05AG03 Efavirenz (DMP-266) (STOCRIN, SUSTIVA) J05AG04 Etravirine (TMC 125) J05AG05 Rilpivirine (TMC-278) J05AG06 Doravirine J05AJ04 Cabotegravir J05AR01 Combivir (Zidovudine/Lamivudine) J05AR02 Kivexa (Lamivudine/Abacavir) J05AR03 Truvada (Tenofovir/Emtricabine) J05AR04 Trizivir (Zidovudine/Lamivudine/Abacavir) J05AR05 Douvir-N (Zidovudine/Lamivudine/Nevirapine) J05AR06 Atripla (Emtricitabine/Tenofovir/Efavirenz) J05AR07 Triomune (Stavudine/Lamivudine/Nevirapine) J05AR08 Eviplera/Complera (Emtricitabine/Tenofovir/Rilpivirine) J05AR09 Stribild (Emtricitabine/Tenofovir/Elvitegravir/Cobicistat) J05AR10 Kaletra/Aluvia (Lopinavir/Ritonavir) J05AR10 Lopinavir/Ritonavir (Kaletra). Former code: J05AE06 J05AR11 Lamivudine, tenofovir disoproxil and efavirenz J05AR12 Lamivudine and tenofovir disoproxil J05AR13 Triumeq (Lamivudine, abacavir and dolutegravir) J05AR14 Darunavir and cobicistat J05AR15 Atazanavir and cobicistat J05AR16 Lamivudine and raltegravir J05AR17 Emtricitabine and tenofovir alafenamide J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine J05AR20 Emtricitabine, Tenofovir Alafenamide and Bictegravir J05AR21 JLC: Juluca (DTG/RPV) J05AR22 Symtuza (Emtricitabine, Tenofovir, Alafenamide, Darunavir and Cobicistat) J05AR24 Lamivudine, Tenofovir, Disoproxil and Doravirine J05AR25 Lamivudine and Dolutegravir J05AX-VIC Vicriviroc (Schering) J05AX07 Enfuvirtide (Fuzeon, T-20) J05AX08 Raltegravir (Merck) J05AX09 Maraviroc (Pfizer) J05AX11 Elvitegravir J05AX12 Dolutegravir L01XX05 Hydroxyurea/Hydroxycarbamid (Litalir) V03AX03 Cobicistat 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 18 Unwanted weight changes 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 4.3 Injection site reaction 4.4 Injection fatigue (not related to safety) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 92.91 Change to generic drug 92.92 Change to branded drug 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 PMTCT 30 ARV as treatment 40 PEP - Post Exposure Prophylaxis 50 PREP 95 Not ascertained 99 Unknown despite attempting ascertainment J05A ART unspecified J05A-BEV Bevirimat J05A-PBT Participant in Blinded Trial J05AE PI unspecified J05AE-MOZ Mozenavir (DMP-450) J05AE01 Saquinavir (gel, not specified) J05AE01-SQH Saquinavir hard gel (INVIRASE) J05AE01-SQS Saquinavir soft gel (FORTOVASE) J05AE02 Indinavir (CRIXIVAN) J05AE03 Ritonavir (NORVIR) J05AE03-H Ritonavir high dose (NORVIR) J05AE03-L Ritonavir low dose (NORVIR) J05AE04 Nelfinavir (VIRACEPT) J05AE05 Amprenavir (AGENERASE) J05AE07 Fos-amprenavir (Telzir, Lexiva) J05AE08 Atazanavir (Reyataz) J05AE09 Tipranavir (Aptivus) J05AE10 Darunavir (TMC-114, Prezista) J05AF NRTI unspecified J05AF-ALO Alovudine J05AF-AMD Amdoxovir (DADP) J05AF-FOZ Fozivudine tidoxi J05AF-LDN Lodenosine (trialdrug) J05AF-RVT Reverset J05AF01 Zidovudine (AZT, RETROVIR) J05AF02 Didanosine (ddI) (VIDEX) J05AF03 Zalcitabine (ddC) (HIVID) J05AF04 Stavudine (d4T) (ZERIT) J05AF05 Lamivudine (3TC, EPIVIR) J05AF06 Abacavir (1592U89) (ZIAGEN) J05AF07 Tenofovir (VIREAD) J05AF09 Emtricitabine J05AG NNRTI unspecified J05AG-CPV Capravirine J05AG-DPC083 DPC 083 J05AG-DPC961 DPC 961 J05AG-EMV Emivirine (MKC442) J05AG-LOV Loviride J05AG01 Nevirapine (VIRAMUN) J05AG02 Delavirdine (U-90152) (RESCRIPTOR) J05AG03 Efavirenz (DMP-266) (STOCRIN, SUSTIVA) J05AG04 Etravirine (TMC 125) J05AG05 Rilpivirine (TMC-278) J05AR01 Combivir (Zidovudine/Lamivudine) J05AR02 Kivexa (Lamivudine/Abacavir) J05AR03 Truvada (Tenofovir/Emtricabine) J05AR04 Trizivir (Zidovudine/Lamivudine/Abacavir) J05AR05 Douvir-N (Zidovudine/Lamivudine/Nevirapine) J05AR06 Atripla (Emtricitabine/Tenofovir/Efavirenz) J05AR07 Triomune (Stavudine/Lamivudine/Nevirapine) J05AR08 Eviplera/Complera (Emtricitabine/Tenofovir/Rilpivirine) J05AR09 Stribild (Emtricitabine/Tenofovir/Elvitegravir/Cobicistat) J05AR10 Kaletra/Aluvia (Lopinavir/Ritonavir) J05AR10 Lopinavir/Ritonavir (Kaletra). Former code: J05AE06 J05AR11 Lamivudine, tenofovir disoproxil and efavirenz J05AR12 Lamivudine and tenofovir disoproxil J05AR13 Triumeq (Lamivudine, abacavir and dolutegravir) J05AR14 Darunavir and cobicistat J05AR15 Atazanavir and cobicistat J05AR16 Lamivudine and raltegravir J05AR17 Emtricitabine and tenofovir alafenamide J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine J05AX-CAB Cabotegravir (GSK-744) J05AX-VIC Vicriviroc (Schering) J05AX07 Enfuvirtide (Fuzeon, T-20) J05AX08 Raltegravir (Merck) J05AX09 Maraviroc (Pfizer) J05AX11 Elvitegravir J05AX12 Dolutegravir L01XX05 Hydroxyurea/Hydroxycarbamid (Litalir) V03AX03 Cobicistat 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 PMTCT 30 ARV as treatment 40 PEP - Post Exposure Prophylaxis 50 PREP 95 Not ascertained 99 Unknown despite attempting ascertainment 1 homo/bisexual 10 Sexual abuse 2 injecting drug user 3 (1+2) 4 haemophiliac 5 transfusion, non-haemophilia related 6 heterosexual contact 7 (6+2) 8 Perinatal 9 Sexual contact (homo/hetero not specified) 90 other, (specify) 99 unknown 001 World 002 Africa 005 - - South America 009 Oceania 011 - Western Africa 013 - - Central America 014 - Eastern Africa 015 - Northern Africa 017 - Middle Africa 018 - Southern Africa 019 Americas 021 - Northern America 029 - - Caribbean 030 - Eastern Asia 034 - Southern Asia 035 - South-Eastern Asia 039 - Southern Europe 053 - Australia and New Zealand 054 - Melanesia 057 - Micronesia 061 - Polynesia 142 Asia 143 - Central Asia 145 - Western Asia 150 Europe 151 - Eastern Europe 154 - Northern Europe 155 - Western Europe 419 - Latin America and the Caribbean Republic of Kosovo 100 Bulgaria BGR 104 Myanmar MMR 108 Burundi BDI 112 Belarus BLR 116 Cambodia KHM 12 Algeria DZA 120 Cameroon CMR 124 Canada CAN 132 Cape Verde CPV 136 Cayman Islands CYM 140 Central African Republic CAF 144 Sri Lanka LKA 148 Chad TCD 152 Chile CHL 156 China CHN 16 American Samoa ASM 170 Colombia COL 174 Comoros COM 175 Mayotte MYT 178 Congo COG 180 Democratic Republic of the Congo COD 184 Cook Islands COK 188 Costa Rica CRI 191 Croatia HRV 192 Cuba CUB 196 Cyprus CYP 20 Andorra AND 203 Czech Republic CZE 204 Benin BEN 208 Denmark DNK 212 Dominica DMA 214 Dominican Republic DOM 218 Ecuador ECU 222 El Salvador SLV 226 Equatorial Guinea GNQ 231 Ethiopia ETH 232 Eritrea ERI 233 Estonia EST 234 Faeroe Islands FRO 238 Falkland Islands (Malvinas) FLK 24 Angola AGO 242 Fiji FJI 246 Finland FIN 248 Åland Islands ALA 250 France FRA 254 French Guiana GUF 258 French Polynesia PYF 262 Djibouti DJI 266 Gabon GAB 268 Georgia GEO 270 Gambia GMB 275 Occupied Palestinian Territory PSE 276 Germany DEU 28 Antigua and Barbuda ATG 288 Ghana GHA 292 Gibraltar GIB 296 Kiribati KIR 300 Greece GRC 304 Greenland GRL 308 Grenada GRD 31 Azerbaijan AZE 312 Guadeloupe GLP 316 Guam GUM 32 Argentina ARG 320 Guatemala GTM 324 Guinea GIN 328 Guyana GUY 332 Haiti HTI 336 Holy See VAT 340 Honduras HND 344 China, Hong Kong Special Administrative Region HKG 348 Hungary HUN 352 Iceland ISL 356 India IND 36 Australia AUS 360 Indonesia IDN 364 Iran (Islamic Republic of) IRN 368 Iraq IRQ 372 Ireland IRL 376 Israel ISR 380 Italy ITA 384 Côte d'Ivoire CIV 388 Jamaica JAM 392 Japan JPN 398 Kazakhstan KAZ 4 Afghanistan AFG 40 Austria AUT 400 Jordan JOR 404 Kenya KEN 408 Democratic People's Republic of Korea PRK 410 Republic of Korea KOR 414 Kuwait KWT 417 Kyrgyzstan KGZ 418 Lao People's Democratic Republic LAO 422 Lebanon LBN 426 Lesotho LSO 428 Latvia LVA 430 Liberia LBR 434 Libya LBY 438 Liechtenstein LIE 44 Bahamas BHS 440 Lithuania LTU 442 Luxembourg LUX 446 China, Macao Special Administrative Region MAC 450 Madagascar MDG 454 Malawi MWI 458 Malaysia MYS 462 Maldives MDV 466 Mali MLI 470 Malta MLT 474 Martinique MTQ 478 Mauritania MRT 48 Bahrain BHR 480 Mauritius MUS 484 Mexico MEX 492 Monaco MCO 496 Mongolia MNG 498 Republic of Moldova MDA 499 Montenegro MNE 50 Bangladesh BGD 500 Montserrat MSR 504 Morocco MAR 508 Mozambique MOZ 51 Armenia ARM 512 Oman OMN 516 Namibia NAM 52 Barbados BRB 520 Nauru NRU 524 Nepal NPL 528 Netherlands NLD 531 Curaçao CUW 533 Aruba ABW 534 Sint Maarten (Dutch part) SXM 535 Bonaire, Saint Eustatius and Saba BES 540 New Caledonia NCL 548 Vanuatu VUT 554 New Zealand NZL 558 Nicaragua NIC 56 Belgium BEL 562 Niger NER 566 Nigeria NGA 570 Niue NIU 574 Norfolk Island NFK 578 Norway NOR 580 Northern Mariana Islands MNP 583 Micronesia (Federated States of) FSM 584 Marshall Islands MHL 585 Palau PLW 586 Pakistan PAK 591 Panama PAN 598 Papua New Guinea PNG 60 Bermuda BMU 600 Paraguay PRY 604 Peru PER 608 Philippines PHL 612 Pitcairn PCN 616 Poland POL 620 Portugal PRT 624 Guinea-Bissau GNB 626 Timor-Leste TLS 630 Puerto Rico PRI 634 Qatar QAT 638 Réunion REU 64 Bhutan BTN 642 Romania ROU 643 Russian Federation RUS 646 Rwanda RWA 652 Saint-Barthélemy BLM 654 Saint Helena SHN 659 Saint Kitts and Nevis KNA 660 Anguilla AIA 662 Saint Lucia LCA 663 Saint-Martin (French part) MAF 666 Saint Pierre and Miquelon SPM 670 Saint Vincent and the Grenadines VCT 674 San Marino SMR 678 Sao Tome and Principe STP 68 Bolivia (Plurinational State of) BOL 680 Sark 682 Saudi Arabia SAU 686 Senegal SEN 688 Serbia SRB 690 Seychelles SYC 694 Sierra Leone SLE 70 Bosnia and Herzegovina BIH 702 Singapore SGP 703 Slovakia SVK 704 Viet Nam VNM 705 Slovenia SVN 706 Somalia SOM 710 South Africa ZAF 716 Zimbabwe ZWE 72 Botswana BWA 724 Spain ESP 728 South Sudan SSD 729 Sudan SDN 732 Western Sahara ESH 740 Suriname SUR 744 Svalbard and Jan Mayen Islands SJM 748 Swaziland SWZ 752 Sweden SWE 756 Switzerland CHE 76 Brazil BRA 760 Syrian Arab Republic SYR 762 Tajikistan TJK 764 Thailand THA 768 Togo TGO 772 Tokelau TKL 776 Tonga TON 780 Trinidad and Tobago TTO 784 United Arab Emirates ARE 788 Tunisia TUN 792 Turkey TUR 795 Turkmenistan TKM 796 Turks and Caicos Islands TCA 798 Tuvalu TUV 8 Albania ALB 800 Uganda UGA 804 Ukraine UKR 807 The former Yugoslav Republic of Macedonia MKD 818 Egypt EGY 826 United Kingdom of Great Britain and Northern Ireland GBR 830 Channel Islands 831 Guernsey GGY 832 Jersey JEY 833 Isle of Man IMN 834 United Republic of Tanzania TZA 84 Belize BLZ 840 United States of America USA 850 United States Virgin Islands VIR 854 Burkina Faso BFA 858 Uruguay URY 860 Uzbekistan UZB 862 Venezuela (Bolivarian Republic of) VEN 876 Wallis and Futuna Islands WLF 882 Samoa WSM 887 Yemen YEM 894 Zambia ZMB 90 Solomon Islands SLB 92 British Virgin Islands VGB 96 Brunei Darussalam BRN 100 White/Caucasian 110 > White, European 200 Black 204 > Other Black 210 > Sub-Saharan African 220 > Caribbean 230 > African-American 250 > Black, African 300 Hispanic/Latinx 400 Asian 405 > Other asian 410 > East Asian (e.g. Chinese, Japanese) 411 > > Chinese 412 > > Japanese 420 > Southeast Asia (e.g. Thai, Vietnamese, Philippino) 421 > > Indian Subcontinent (Indian, Pakistani, Bangladeshi) 430 > South Asian (e.g. Indian, Pakistani) 800 Other ethnic groups 810 > Maghrebian 820 > Middle East/Arab 830 > Turkish 840 > Roma people/Gypsy (whichever is term is acceptable) 850 > Indigenous people from Americas or Alaska Native 860 > Indigenous people from other continents/locations 900 Mixed race/ethnicity 910 Do not want to disclose 980 Prohibited 999 Unknown 1 primary education (ISCED97-1) 2 lower secondary (ISCED97-2) OR end of basic education 3 upper secondary or post-secondary non-tertiary (ISCED97 3 and 4) 4 university or post-graduate (ISCED97 5A and 5B) 8 other, only if none of the codes 0 to 4 applies 9 Unknown AMI Acute myocardial infarction ARFI Acoustic Radiation Force Impulse ASP Invasive aspergillosis AVN Avascular necrosis in the femural head BACT Bacteremia BART Bartonellosis BMD-F Bone Mass Density of the femur BMD-H Bone Mass Density of the hip BMD-S Bone Mass Density of the spine CERC Cervical cerclage CHAG Chagas disease (American trypanosomiasis) of the CNS CLD Chronic liver disease COVAM Hospital admission due to infection with SARS-CoV-2 CTAB CT abdomen DIA Diabetes mellitus ENDO Endocarditis ESLD End stage liver disease ESRD End stage renal disease FAT Fatal case with insufficient data FIBS Fibroscan stiffness (add elasticity value in CEP_V) FRA Bone fracture (irrespective of location) HOSP Hospitalisation ICP Invasive Cardiovascular Procedures ICU Admission for the ICU JAUN Jaundice KIDT Kidney transplantation LAC Lactic acidosis LEIS Leishmaniasis, visceral LIVB Liver biopsy MCDI Microsporidosis diarrhoes (dur. > 1 month) MENI Meningitis NADM Non-AIDS defining malignancies NOCA Nocardiosis OSTI Ostitis PAN Pancreatitis PCE Pneumocystis carinii extrapulmonary PERI Spontaneous bacterial peritonitis PMAR Penicillium marneffei, disseminated PNEU Pneumonia PYEL Pyelonephritis REQU Rhodococcus equi disease STR Stroke (infarction or haemorrhagia) SYPH Syphilis USAB Ultrasound imaging of the abdomen ANEM Anemia (<10g/l) ANEMBL Severe anemia requiring blood transfusion DIC Disseminated intravascular coagulation (DIC) ENDOM Endometritis FEV Fever (> 38 0C and > 1 day) HEMATOMA Hematoma HEMOR Hemorrhage PERIT Peritonitis PNEU Pneumonia PREECL Preeclampsia/eclampsia PSY Psychosis SEPSIS Sepsis (fever and pos blood culture) SUBI Subileus/ ileus THROMB Thromboembolism URITINF Urinary tract infection WOUINF Wound infection DEVD Developmental delay OABN Other abnormal findings (use with AE_DESCRIP) ONEU Other neurological symptoms (use with AE_DESCRIP) SEIZ Seizures AMI DAMI Definitive Myocardial infarction AMI PAMI Possible Myocardial infarction BMD-F BMDA Bone mass density area BMD-F BMDT Bone mass density T-score BMD-F BMDZ Bone mass density Z-score BMD-H BMDA Bone mass density area BMD-H BMDT Bone mass density T-score BMD-H BMDZ Bone mass density Z-score BMD-S BMDA Bone mass density area BMD-S BMDT Bone mass density T-score BMD-S BMDZ Bone mass density Z-score COVAM DIY Dialysis COVAM ECMO Extra Corporal Membran Oxygenation COVAM HFOS High-flow oxygen supply COVAM IMV Invasive mechanical ventilation COVAM NIMV Non-invasive mechanical ventilation COVAM UNKP Unspecified admission ESLD ASCI Ascites ESLD HEP Hepatic encephalopathy grade III or IV ESLD HESY Hepatorenal syndrome ESLD LIVT Liver transplantation ESLD OESO Oesophageal variceal bleeding ESLD UNKP Unspecified ESLD ESRD KDIA Peritoneal or haemo- dialysis for a duration of more than 3 consecutive months (for chronic renal disease) ESRD KIDT Kidney transplant (for chronic renal disease) ESRD UNKP Unspecified ESRD FRA CESP Cervical spine FRA COLB Collar bone FRA FABO Facial bones (including nose) FRA FEM Femur FRA FING Fingers FRA HIP Hip FRA LOAR Lower arm (including hands) FRA LOLG Lower leg (including feet) FRA LUSP Lumbar spine FRA OTH Other FRA PEL Pelvic FRA RIB Rib FRA SHOU Shoulder FRA SKUL Skull FRA TOE Toes FRA TOSP Thoracic spine FRA UNKP Unknown fracture location FRA UPAR Upper arm HEP I Hepatic encephalopathy stage I HEP II Hepatic encephalopathy stage II HEP III Hepatic encephalopathy stage III HEP III+IV Hepatic encephalopathy stage III or IV HEP IV Hepatic encephalopathy stage IV ICP ANG Invasive Cardiovascular Procedures: Coronary angioplasty/stenting ICP BYP Invasive Cardiovascular Procedures: Coronary artery by-pass grafting ICP END Invasive Cardiovascular Procedures: Carotic endarterectomy ICP UNKP Unknown ICP LIVB F0 no fibrosis LIVB F1 portal fibrosis without septa LIVB F2 portal fibrosis with few septa LIVB F3 numerous septa without cirrhosis LIVB F4 cirrhosis NADM ALL Leukemia: Acute lymphoid NADM AML Leukemia: Acute myeloid NADM ANAL Anal dysplasia, grade 2 or higher NADM ANUS Anal cancer NADM BLAD Bladder cancer NADM BRAIN Brain cancer NADM BRCA Breast cancer NADM CERV Cervical dysplasia/carcinoma in situ, grade 2 or higher NADM CLL Leukemia: Chronic lymphoid NADM CML Leukemia: Chronic myeloid NADM COLO Colon cancer NADM COTC Connective tissue cancer NADM HDL Hodgkin lymphoma NADM HENE Head and neck cancer NADM HENECOC Oral cavity cancer NADM HENEHPC Hypopharyngeal cancer NADM HENELXC Laryngeal cancer NADM HENEOPC Oropharyngeal cancer NADM HENERPC Rhinopharyngeal cancer NADM HENESGC Saliva gland cancer NADM HENESNC Sino/nasal cavity cancer NADM HENETYC Thyroid cancer NADM KIDN Kidney cancer NADM LEUK Leukemia: unspecified NADM LIPC Lip cancer NADM LIVR Liver cancer NADM LUNG Lung cancer NADM MALM Malignant melanoma NADM MEAC Metastasis: of adenocarcinoma NADM MEOC Metastasis: of other cancertype NADM MESC Metastasis: of squamuos cell carcinoma NADM META Metastasis: unspecified NADM MULM Multiple myeloma NADM PENC Penile cancer NADM PROS Prostate cancer NADM RECT Rectum cancer NADM STOM Stomach cancer NADM TESE Testicular seminoma NADM UNKP Unknown NADM type NADM UTER Uterus cancer STR SHAE Stroke: Haemorrhagia STR SINF Stroke: Infarction STR SUNK Stroke: Unknown ARFI Numeric value in (m/s) BMD-S, BMD-H, BMD-F BMDA Numeric value: min: 0, max: 50, unit: g/cm2 (2 decimals) BMD-S, BMD-H, BMD-F BMDT, BMDZ Numeric value: Standard deviation (SD), max: +10, min: -10 COVAM 1 = Hospital admission in non-ICU ward, 2 = Hospital admission in ICU ward ESLD HEP 1 = Hepatic encephalopathy stage I, 2 = Hepatic encephalopathy stage II, 3 = Hepatic encephalopathy stage III, 4 = Hepatic encephalopathy stage IV, 9 = Hepatic encephalopathy unknown stage FIBS Fibroscan elasticity given in (KPa) FRA 1 = Traumatic, 2 = Osteoporotic/Fragility, 3 = Pathologic , 9 = Unknown HOSP Number of days addmited to the hospital ICU Number of days addmited to the ICU ANGC Angular cheilitis BCGD BCG disease - disseminated BCIR Recurrent severe persumed bacterial infection (excluding pneumonia) BCNE Bacterial pneumonia, recurrent (>2 episodes within 1 year) BLD Unexplained anaemia (<8g/dl), and or neutropaenia (<500/mm3 - 2; <1000/mm3 - children), and or thrombocytopaenia (<50000/mm3) > 1 month CANE Candidiasis oesophogeal CANM Candidiasis (oral) (outside neonatal period) CANO Candidiasis (oesophogeal, bronchi, trachea, or lungs) CANT Candidiasis (bronchi, trachea, or lungs) CLD Chronic HIV-associated lung disease CMO HIV-associated cardiomyopathy CMVO Cytomegalovirus other Location (site other than liver, Spleen or lymph nodes) CMVR Cytomegalovirus (CMV) chorioretinitis (onset at age > 1 month) COCC Coccidioidomycosis, disseminated or extrapulmonary CRCO Cryptococcosis, extrapulmonary CRSP Cryptosporidiosis (duration > 1 month) CRVC Cervical cancer (invasive) DEM AIDS dementia complex DEM AIDS dementia complex DIAC Unexplained chronic diarrhoea (> 1 month for adults; > 14 days for children) ENC HIV encephalopathy FBLS Focal Brain lesion FEVC Unexplained persistent fever (> 1 month) FNIF Fungal nail infections of fingers HERP Herpes simplex virus ulcers (duration > 1 month) or pneumonitis/esophagitis HERPV Visceral Herpes simplex infection HIST Histoplasmosis, extrapulm. HZS Herpes zoster (single dermatome) ISDI Isosporiasis diarrhoea (duration > 1 month) KS Kaposi Sarcoma LEIS Leishmaniasis visceral LEU Progressive multifocal leucoencephalopathy LIP Symptomatic lymphoid interstitial pneumonitis LNTB Lymph node tuberculosis MC Mycobact. avium complex (MAC) or Kanasii, extrapulm. MCDI Microsporidosis diarrhoea (duration > 1 month) MCP Mycobact. tuberculosis pulm. MCPO Mycobact. pulm., other MCX Mycobact. tuberculosis extrapulm MCXO Mycobact. extrapulm., other MNUM Unexplained moderate malnutrition or wasting MNUS Unexplained severe malnutrition or wasting MYCD Any disseminated mycosis NHG Non-Hodgkin Lymphoma - not specified NHG Non-Hodgkin Lymphoma -not specified NHGB Non-Hodgkin Lymphoma – Burkitt (Classical or Atypical) NHGI Non-Hodgkin Lymphoma – Diffuse large B-cell lymphoma (Immunoblastic or Centroblastic) NHGP Non-Hodgkin Lymphoma - Primary Brain Lymphoma NHGU Non-Hodgkin Lymphoma - Unknown/other histology NPO HIV-associated nephropathy NUS Acute necrotising ulcerative stomatitis, gingivitis or periodontitis OHLP Oral hairy leukoplakia ORUL Recurrent oral ulcerations PCP Pneumocystis carinii pneumonia (PCP) PGL Persistent Generalized Lymphadenopathy PPE Papular pruritic eruptions RTIR Recurrent or chronic respiratory tract infection (RTIs, sinusitis, bronchitis, otitis media, otorrhea, pharyngitis) SAM Salmonella bacteriaemia (non-tyhpoid) (recurrent) SEBD Seborrheic dermatitis TOX Toxoplasmosis, brain WAST HIV Wasting Syndrome WTLM Moderate unexplained weight loss (<10% of body weight) WTLS Severe unexplained weight loss (>10% of body weight) A CA-DER Dermatitis A CA-HEY Hepatomegaly A CA-LYM Lymphadenopathy A CA-PAR Parotitis A CA-SPL Splenomegaly A CA-URI Recurrent or persist. UR infection, sinusitis, or otitis media B CB-ANE Anemia B CB-BMP Bacterial meningitis, pneumonia, or sepsis B CB-CAN Candidiasis oropharyngeal for >2 months (age>6) B CB-CMN CMV onset before 1 month B CB-CMY Cardiomyopathy B CB-DIA Diarrhea (recurrent or chronic) B CB-FEV Fever (lasting >1 month) B CB-HCV HSV bronchitis, pneumonitis, esophagitis (<1 month) B CB-HEP Hepatitis B CB-HSS Herpes simplex stomatitis (>2 episodes in 1 year) B CB-HZO Herpes zoster, multidermatomal or relapse B CB-LEI Leiomyosarcoma B CB-LYM Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex B CB-NEP Nephropathy B CB-NOC Nocardiosis B CB-TON Toxoplasmosis (start before 1 month) B CB-VAR Varicella, disseminated C CC-COM Cryptococcal meningitis C CC-EPD Pneumocystis disease, extrapulmonary C CC-GEN M. genavense disease C CC-ICC Carcinoma, cervical, invasive C CC-ILE Intracerebral lesions, indeterminated C CC-LOB Lymphoma,primary, cerebral C CC-TOD Toxoplasmosis disseminated BCNE Bacterial pneumonia, recurrent (>2 episodes within 1 year) D New X-ray evidence not present earlier and culture of pathogen that typically causes pneumonia (other than P .carinii or M. tuberculosis BCNE Bacterial pneumonia, recurrent (>2 episodes within 1 year) P Acute radiological findings (new X-ray evidence not present earlier) and acute clinical findings CANO Candidiasis, oesophageal, bronchi, trachea, or lungs D/A Gross inspection by endoscopy/autopsy or by microscopy (histology) CANO Candidiasis, oesophageal, bronchi, trachea, or lungs P Recent onset retrosternal pain on swallowing and confirmed oral or pharyngeal candidiasis CMVO CMV – other location D/A Microscopy (histology or cytology) CMVR Cytomegalovirus (CMV) chorioretinitis P Loss of vision and characteristic appearance on serial ophtalmoscopy, progressing over serial months CRCO Cryptococcosis, extrapulm. D/A Microscopy, culture of, or antigen detection in affected tissue CRSP Cryptosporidiosis (duration > 1 month) D/A Microscopy. Duration of diarrhoea for more then 1 month CRVC Cervical Cancer D/A Histology DEM AIDS dementia complex D Disabling cognitive and/or motor dysfunction, or milestone loss in a child, and no other causes by CSF exam and brain imaging or by autopsy DEM AIDS dementia complex P Same as above but no CSF and brain imaging performed FBLS Focal Brain lesion ? TODO:: To be updated ASAP HERP Herpes simplex virus ulcers (duration > 1 month) or pneumonitis/esophagitis D Microscopy, culture of, or antigen detection in affected tissue HIST Histoplasmosis, extrapulm. D/A Microscopy, culture of, or antigen detection in affected tissue ISDI Isosporiasis diarrhoea (duration > 1 month) D/A Microscopy (histology or cytology). Duration of diarrhoea for more than 1 month KS Kaposi Sarcoma D/A Histology KS Kaposi Sarcoma P Characteristic erythematous/violaceous plaque-like lesion on skin or mucous membranes LEIS Leishmaniasis, visceral D/A Histology or culture of Leishmania amastigotes in bone marrow or detection of amastigotes in tissue/fluid from affected organ in a patient with symptoms and signs consistent with disseminated Leishmaniasis LEU Progressive multifocal leucoencephalopathy D/A Microscopy (histology or cytology) LEU Progressive multifocal leucoencephalopathy P Progressive deterioration in neurological function and CT/MR scan evidence MC Mycobact. avium complex (MAC) or Kanasii, extrapulm. D Culture MCDI Microsporidosis diarrhoes (dur. > 1 month) D/A Stool microscopy or rectal biopsy in patient with persistent diarrhoea MCP Mycobact. tuberculosis pulm. D Culture MCPO Mycobact. pulm., other D Culture (indicate type) MCPO Mycobact. pulm., other P Acid fast bacteria (species not identified by culture) in sputum MCX Mycobact. tuberculosis extrapulm D Culture MCXO Mycobact. extrapulm., other D Culture (indicate type) MCXO Mycobact. extrapulm., other P Acid fast bacteria (species not identified by culture) on microscopy of normally sterile body fluid/tissue NHGB Non-Hodgkin Lymphoma – Burkitt (Classical or Atypical) D Histology NHGI Non-Hodgkin Lymphoma – Diffuse large B-cell lymphoma (Immunoblastic or Centroblastic) D Histology NHGP Non-Hodgkin Lymphoma - Primary Brain Lymphoma D TODO:: To be updated ASAP NHGP Non-Hodgkin Lymphoma - Primary Brain Lymphoma P Recent onset of focal neurological symptoms and signs or reduced level of consciousness, CT/MR scan evidence of a lesion or lesions having mass effect, no response to toxo therapy, no evidence of lymphoma outside the brain NHGU Non-Hodgkin Lymphoma - Unknown/other histology ? TODO:: To be updated ASAP PCP Pneumocystis carinii pneumonia (PCP) D Microscopy (histology or cytology) PCP Pneumocystis carinii pneumonia (PCP) P Recent onset of dyspnoea on exertion or dry cough, and diffuse bilateral infiltrates on chest X-ray and pO2 <70 mmHg and no evidence of bacterial pneumonia SAM Salmonella bacteriaemia (non-tyhpoid) (recurrent) D Culture TOX Toxoplasmosis, brain D Microscopy (histology/cytology) TOX Toxoplasmosis, brain P Recent onset focal neurological abnormalities or reduced level of consciousness, and mass effect lesion on scan, and specific therapy response WAST HIV Wasting Syndrome D Weight loss (over 10% of baseline) with no other cause, and 30 days or more of either diarrhoea or weakness with fever 1 Definitive diagnosis 2 Presumptive diagnosis 3 Diagnosis from autopsy 4 Diagnosis from registry 1 Abdominal 10 Pleural 2 Bone/Joint 3 CNS/Meningeal 4 Genitourinary 5 Laryngeal 6 Lymphatic 7 Meningeal/CNS 8 Miliary 88 Not applicable 9 Pericardial 95 Not ascertained 99 Unknown 0 Not evaluated 1 Cured (lab confirmation) 2 Treatment completed (but cure not confirmed) 3 Treatment failed 4 Died 5 LTFU/Default (from disease Treatment esp. TB, not necessarily from HIV clinic) 9 Unknown A1C Haemoglobin A1C ACRA Albumin Creatinin Ratio AFP Alfa Fetoprotein ALB Albumine ALP Alkaline Phosphatase ALT Alanin-Aminotransferase AMY Amylase AST Aspartat aminotransferase BIL Total Bilirubin BUN Blood Urea Nitrogen CD3 CD3 CD3P % CD3 of leukocytes CD8 CD8 CD8P % CD8 of leukocytes CHOL Total Cholesterol CL- Cl- CRE Creatinine DIPB Dipstick result for blood in Urine DIPG Dipstick result for glucose in Urine DIPK Dipstick result for ketones in Urine DIPLE Dipstick result for leucocyte esterase in Urine DIPP Dipstick result for protein in Urine GGT Gamma-glutamyltransferase GLUC Glucose HAEM Haemoglobin HDL Serum HDL HEMA Hematocrit IGRA Interferon-Gamma Release Assay INR Quick/INR LACT Lactate LDL Serum LDL LEUK Leukocytes LYM Lymphocytes LYMP % Lymphocytes of leukocytes MCV MCV NA+ Na+ NEU Neutrophils PCRA Protein Creatinin Ratio PHA PH arterial PHV PH venous PP PP factor (II, VII, X) PROT Protein PSA Prostate-specific antigen PTH Parathyroid Hormone PTR Prothrombin rate TBC TB culture TBGX TB GeneXpert TBHIST TB histology TBM TB smear/microscopy TBNAAT TB NAAT/LPA (non-GeneXpert) TBRES Mycobacterium Tuberculosis resistance testing THR Thrombocytes TRIG Serum Triglyceride URA Uric acid UREA Urea/Blood Urea Nitrogen 1 mmol/L 10 cells/µL 11 µkat/L 12 % 13 µg/L = ng/mL 14 mg/24h 15 mg/mmol 16 fl (Femtoliter) 17 µg/mL = mg/L 18 mmol/mol 2 g/L 3 g/dL 4 mg/dL 5 IU/L (u/L) 6 µmol/L 7 INR 8 1E+9/L 9 1E+6/L 99 no units (e.g. for Dipstick results) CSF Cerebrospinal fluid OTH Other P Plasma S Serum SA Saliva SP Sputum U Urine U24 24h Urine UNK Unknown WB Whole blood 1 mmHg 2 cmHg 3 Kpa 10 Roche 1.0 15 Roche 1.5 ultra-sensitive 19 Any Roche (unspecified) 20 NASBA 21 NASBA ultra-sensitive 29 Any NASBA (unspecified) 31 Chiron b-DNA 1.0 32 Chiron b-DNA 2.0 33 Chiron b-DNA 3.0 39 Any Chiron (unspecified) 40 Abbott ultra-sensitive 41 Abbott LCx 42 Abbott RealTime HIV-1 m2000 5 Roche TaqMan 50 Monitor 1.0 51 Monitor 1.0 ultra-sensitive 55 Monitor 1.5 56 Monitor 1.5 ultra-sensitive 59 Monitor unspecified 65 Cobas 1.5 66 Cobas 1.5 ultra-sensitive 90 Other 99 Unknown BVA Bacterial vaginosis unspecified method BVAC Bacterial vaginosis - clinical BVAG Bacterial vaginosis - gram stain CHLA Chlamydia CMVA CMV antibodies COVA SARS-CoV-2 Antibody test COVRNA SARS-CoV-2 PCR CRAG Cryptococcal Antigen test (CrAg) CRYP Cryptococcal test - other/type unknown GONO Gonorrhoea HBV Marker for hepatitis B infection (=HBVAC) - test unknown HBVAC HBV antibody (core) HBVACIGG HBG antibody (core IgG) HBVACIGM HBV antibody (core IgM) HBVAE HBV antibody (envelope) HBVAS HBV antibody (surface) HBVD HBV-dna HBVGE HBV antigen (envelope) HBVGS HBV antigen (surface) HCV Marker for hepatitis C infection - test unknown HCVA HCV antibody HCVBD HCV b-dna HCVG HCV antigen HCVR HCV-rna HDVA Hepatitis delta antibody HIV-1DNA HIV-1 DNA PCR test (qualitative) HIV-1R HIV-1 rapid test HIV-1S HIV-1 serology test (ELISA, Western Blot) HIV-2DNA HIV-2 DNA PCR test (qualitative) HIV-2R HIV-2 rapid test HIV-2S HIV-2 serology test (ELISA, Western Blot) HPV Human Papillomavirus MYCO Mycoplasma P24AG P24 Ag RUB Rubella STR Streptococcus, group B SYPHCON Syphilis Confirmatory (FTA-Abs, MHA-TB, TPPA, EIA) SYPHDV Syphilis Direct Visualization (Darkfield microscopy) SYPHSC Syphilis Screening (RPR, VDRL) TOXA Toxo antibodies UREP Ureaplasma 1 copies/mL 2 IU/mL 3 Geq (millions of genome equivalent) 1 Roche qualitative (Amplicor) [HCV and HBV] 10 Rapid diagnostic test -3rd generation [HIV] 11 Rapid diagnostic test -4th generation [HIV] 12 Self-test-oral [HIV] 13 Self-test-blood-based [HIV] 14 Immunoassay (EIA, CLIA, ECL) - 3rd generation [HIV] 15 Immunoassay (EIA,CLIA, ECL) plus p24 - 4th generation [HIV] 16 WB: Western blot/immunoblot [HIV] 17 NAT (Nucleic Acid Test) [HIV] 2 Roche quantitative test for HBV (Cobas Amplicor HBV monitor) 3 Bayer Bdna quantitative [HCV] 4 Bayer Bdna quantitative [HBV] 5 Roche Taqman 6 Abbott Real Time [HCV and HBV] 7 Siemens VERSANT [HCV and HBV] DNA (bNA) 8 Quiagen artus [HCV and HBV] PCR kit 9 Other 0 Patient was not infected (mainly for children) 1 Patient lost to follow-up / not known to be dead 2 Patient has not had visit within required amount of time 2.1 Patient did not respond to several invitations 3 Patient moved away 3.1 Patient moved to another country 4 Patient moved and is followed by another centre 4.1 Paediatric patient transferred to adult care 5 Patients decision 5.1 Patients caretaker wanted to discontinue (for children) 6 Consent withdrawn 7 Incarceration/jail 8 Institutionalisation (drug treatment, psychological …etc.) 9 Other 01 AIDS (ongoing active disease) 01.1 Infection 01.2 Malignancy 02 Infection (other than 01.1) 02.1 Bacterial 02.1.1 Bacterial with sepsis 02.2 Others 02.2.1 Others with sepsis 02.3 Unknown aetiology 02.3.1 Unknown with sepsis 03 Chronic viral hepatitis (progression of/complication to) 03.1 HCV 03.1.1 HCV with cirrhosis 03.1.2 HCV with liver failure 03.1.3 HCV with liver cancer 03.2 HBV 03.2.1 HBV with cirrhosis 03.2.2 HBV with liver failure 03.2.3 HBV with liver cancer 04 Malignancy (other than 01.2 and 03, 03.1, 03.2) 04.03 ANUS - Anal cancer 04.04 BLAD - Bladder cancer 04.05 BONE - Bone cancer 04.06 BRAC - Brain cancer 04.07 BRCA - Breast cancer 04.10.1 ALL - Leukaemia: Acute lymphoid 04.10.2 AML - Leukaemia: Acute myeloid 04.10.3 CLL - Leukaemia: Chronic lymphoid 04.10.4 CML - Leukaemia: Chronic myeloid 04.10.9 LEUK - Leukaemia: unspecified 04.11 COTC - Connective tissue cancer 04.12 ESOP - Esophagus cancer 04.13 GALL - Gallbladder cancer 04.14 GYCA - Gynaecologic cancer 04.15 HDL - Hodgkin lymphoma 04.16 HENE - Head and neck (incl. face) cancers 04.17 KIDN - Kidney cancer 04.18 COLO - Colon cancer 04.19 LIPC - Lip cancer 04.20 LIVR - Liver cancer 04.21 LUNG - Lung cancer 04.22 MALM - Malignant melanoma 04.27 MULM - Multiple myeloma 04.29 PANC - Pancreas cancer 04.31 PENC - Penile cancer 04.32 PROS - Prostate cancer 04.33 RECT - Rectum cancer 04.34 STOM - Stomach cancer 04.35 TESE - Testicular seminoma 04.36 UTER - Uterus cancer 04.40.1 MEAC - Metastasis: of adenocarcinoma 04.40.2 MEOC - Metastasis: of other cancer type 04.40.3 MESC - Metastasis: of squamuos cell carcinoma 04.40.9 META - Metastasis: unspecified 04.90 OTH - Other Malignancy Type 04.99 UNKP - Unknown Malignancy Type 05 Diabetes Mellitus (complication to) 06 Pancreatitis 07 Lactic acidosis 08 MI or other ischemic heart disease 08.1 AMI 08.1.1 Definitive AMI (Dundee 1) 08.1.2 Possible AMI (Dundee 2/9) 08.2 Other ischemic heart disease 09 Stroke 10 Gastro-intestinal haemorrhage (if chosen, specify underlying cause) 11 Primary pulmonary hypertension 12 Lung embolus 13 Chronic obstructive lung disease 14 Liver failure (other than 03, 03.1, 03.2) 15 Renal failure 16 Accident or other violent death (not suicide) 17 Suicide 18 Euthenasia 19 Substrance abuse (active) 19.1 Chronic Alcohol abuse 19.2 Chronic intravenous drug-use 19.3 Acute intoxication 20 Haematological disease (other causes) 21 Endocrine disease (other causes) 22 Psychiatric disease (other causes) 22.1 Mental and behavioural disorders due to use of psychoactive substances (other than alcohol and intravenous opioids) 22.2 Schizophrenia, schizotypal and delusional Disorders 22.3 Mood /Affective disorders (Major depressive disorder, Bipolar disorder and other mood disorders) 22.4 Neurotic, stress-related and somatoform disorders (including anxiety disorders, phobias, OCD, stress reaction, dissociative disorders, somatoform disorders) 22.5 Behavioral syndromes associated with physiological disturbances and physical factors (including eating disorders, sleep disorders, sexual disorders) 22.90 Other psychiatric disorders 23 CNS disease (other causes) 23.1 Movement disorders (Parkinson’s disease; dystonias and Parkinson-like syndromes) 23.2 Degenerative disorders of the central nervous system (Alzheimer's disease; Creutzfeldt–Jakob disease and other degenerative diseases of nervous system) 23.3 Demyelinating diseases of the central nervous system (Multiple sclerosis, other demyelinating diseases) 23.4 Epilepsy (including localised and generalized epilepsy and epileptic syndromes) 23.5 Polyneuropathies (Guillain–Barré syndrome and other polyneuropathies/disorders of the peripheral nervous system) 23.6 Diseases of myoneural junction and muscle (Miastenia gravis and other myoneural disorders) 23.90 Other disorders of the nervous system 24 Heart or vascular (other causes) 25 Respiratory disease (other causes) 26 Digestive system disease (other causes) 27 Skin and motor system disease (other causes) 28 Urogential disease (other causes) 29 Obstetric complications 30 Congenital disorders 31 Symptoms caused by mitochondrial toxicity (other than 06, 07) 32 Bleeding (haemophilia) 33 Sudden infant death 33.1 Child abuse 90 Other causes 91 Unclassifiable causes 92 Unknown 92.1 Unknown, Competing risks 01.1.1 Tuberculosis 01.1.1.1 Pulmonary tuberculosis 01.1.1.2 Extrapulmonary TB 01.1.1.2.01 Pleura (isolated, without lungs involvement 01.1.1.2.02 Lymphatic intrathoracic (isolated, without lungs involvement) 01.1.1.2.03 Lymphatic extrathoracic 01.1.1.2.04 Pericardia 01.1.1.2.05 Spine 01.1.1.2.06 Bone/joints other than spine 01.1.1.2.07 Meningitis 01.1.1.2.08 CNS other than meningitis 01.1.1.2.09 Genito-urinary tract 01.1.1.2.10 Peritoneal/digestive 01.1.1.2.11 TB with poly-organ failure/ TB sepsis 01.1.1.3 Disseminated tuberculosis 01.1.1.3.01 Lungs 01.1.1.3.02 Miliary 01.1.1.3.03 Pleura 01.1.1.3.04 Lymphatic intrathoracic 01.1.1.3.05 Lymphatic extrathoracic 01.1.1.3.06 Pericardia 01.1.1.3.07 Spine 01.1.1.3.08 Bone/joints other than spine 01.1.1.3.09 Meningitis 01.1.1.3.10 CNS other than meningitis 01.1.1.3.11 Genito-urinary tract 01.1.1.3.12 Peritoneal/digestive 01.1.1.3.13 TB with poly-organ failure/ TB sepsis 01.1.2 other AIDS-defining infection 01.1.2.1 with lungs involvement 01.1.2.2 with CNS involvement 01.2.1 AIDS Malignancy localised to lungs 01.3 IRIS after cART initiation (can only be used as contributing cause of death) 02.1.2 Bacterial pneumonia 02.1.3 Bacterial meningitis 02.2.2 other pneumonia 02.2.3 other with CNS involvement 19.3.1 Toxicity to anti-TB drugs 01 AIDS (ongoing active disease) 01.1 Infection 01.2 Malignancy 02 Infection (other than 01.1) 02.1 Bacterial 02.1.1 Bacterial with sepsis 02.2 Others 02.2.1 Others with sepsis 02.3 Unknown aetiology 02.3.1 Unknown with sepsis 03 Chronic viral hepatitis (progression of/complication to) 03.1 HCV 03.1.1 HCV with cirrhosis 03.1.2 HCV with liver failure 03.1.3 HCV with liver cancer 03.2 HBV 03.2.1 HBV with cirrhosis 03.2.2 HBV with liver failure 03.2.3 HBV with liver cancer 04 Malignancy (other than 01.2 and 03, 03.1, 03.2) 04.03 ANUS - Anal cancer 04.04 BLAD - Bladder cancer 04.05 BONE - Bone cancer 04.06 BRAC - Brain cancer 04.07 BRCA - Breast cancer 04.10.1 ALL - Leukaemia: Acute lymphoid 04.10.2 AML - Leukaemia: Acute myeloid 04.10.3 CLL - Leukaemia: Chronic lymphoid 04.10.4 CML - Leukaemia: Chronic myeloid 04.10.9 LEUK - Leukaemia: unspecified 04.11 COTC - Connective tissue cancer 04.12 ESOP - Esophagus cancer 04.13 GALL - Gallbladder cancer 04.14 GYCA - Gynaecologic cancer 04.15 HDL - Hodgkin lymphoma 04.16 HENE - Head and neck (incl. face) cancers 04.17 KIDN - Kidney cancer 04.18 COLO - Colon cancer 04.19 LIPC - Lip cancer 04.20 LIVR - Liver cancer 04.21 LUNG - Lung cancer 04.22 MALM - Malignant melanoma 04.27 MULM - Multiple myeloma 04.29 PANC - Pancreas cancer 04.31 PENC - Penile cancer 04.32 PROS - Prostate cancer 04.33 RECT - Rectum cancer 04.34 STOM - Stomach cancer 04.35 TESE - Testicular seminoma 04.36 UTER - Uterus cancer 04.40.1 MEAC - Metastasis: of adenocarcinoma 04.40.2 MEOC - Metastasis: of other cancer type 04.40.3 MESC - Metastasis: of squamuos cell carcinoma 04.40.9 META - Metastasis: unspecified 04.90 OTH - Other Malignancy Type 04.99 UNKP - Unknown Malignancy Type 05 Diabetes Mellitus (complication to) 06 Pancreatitis 07 Lactic acidosis 08 MI or other ischemic heart disease 08.1 AMI 08.1.1 Definitive AMI (Dundee 1) 08.1.2 Possible AMI (Dundee 2/9) 08.2 Other ischemic heart disease 09 Stroke 10 Gastro-intestinal haemorrhage (if chosen, specify underlying cause) 11 Primary pulmonary hypertension 12 Lung embolus 13 Chronic obstructive lung disease 14 Liver failure (other than 03, 03.1, 03.2) 15 Renal failure 16 Accident or other violent death (not suicide) 17 Suicide 18 Euthenasia 19 Substrance abuse (active) 19.1 Chronic Alcohol abuse 19.2 Chronic intravenous drug-use 19.3 Acute intoxication 20 Haematological disease (other causes) 21 Endocrine disease (other causes) 22 Psychiatric disease (other causes) 22.1 Mental and behavioural disorders due to use of psychoactive substances (other than alcohol and intravenous opioids) 22.2 Schizophrenia, schizotypal and delusional Disorders 22.3 Mood /Affective disorders (Major depressive disorder, Bipolar disorder and other mood disorders) 22.4 Neurotic, stress-related and somatoform disorders (including anxiety disorders, phobias, OCD, stress reaction, dissociative disorders, somatoform disorders) 22.5 Behavioral syndromes associated with physiological disturbances and physical factors (including eating disorders, sleep disorders, sexual disorders) 22.90 Other psychiatric disorders 23 CNS disease (other causes) 23.1 Movement disorders (Parkinson’s disease; dystonias and Parkinson-like syndromes) 23.2 Degenerative disorders of the central nervous system (Alzheimer's disease; Creutzfeldt–Jakob disease and other degenerative diseases of nervous system) 23.3 Demyelinating diseases of the central nervous system (Multiple sclerosis, other demyelinating diseases) 23.4 Epilepsy (including localised and generalized epilepsy and epileptic syndromes) 23.5 Polyneuropathies (Guillain–Barré syndrome and other polyneuropathies/disorders of the peripheral nervous system) 23.6 Diseases of myoneural junction and muscle (Miastenia gravis and other myoneural disorders) 23.90 Other disorders of the nervous system 24 Heart or vascular (other causes) 25 Respiratory disease (other causes) 26 Digestive system disease (other causes) 27 Skin and motor system disease (other causes) 28 Urogential disease (other causes) 29 Obstetric complications 30 Congenital disorders 31 Symptoms caused by mitochondrial toxicity (other than 06, 07) 32 Bleeding (haemophilia) 33 Sudden infant death 33.1 Child abuse 90 Other causes 91 Unclassifiable causes 92 Unknown 92.1 Unknown, Competing risks 01.1.1 Tuberculosis 01.1.1.1 Pulmonary tuberculosis 01.1.1.2 Extrapulmonary TB 01.1.1.2.01 Pleura (isolated, without lungs involvement 01.1.1.2.02 Lymphatic intrathoracic (isolated, without lungs involvement) 01.1.1.2.03 Lymphatic extrathoracic 01.1.1.2.04 Pericardia 01.1.1.2.05 Spine 01.1.1.2.06 Bone/joints other than spine 01.1.1.2.07 Meningitis 01.1.1.2.08 CNS other than meningitis 01.1.1.2.09 Genito-urinary tract 01.1.1.2.10 Peritoneal/digestive 01.1.1.2.11 TB with poly-organ failure/ TB sepsis 01.1.1.3 Disseminated tuberculosis 01.1.1.3.01 Lungs 01.1.1.3.02 Miliary 01.1.1.3.03 Pleura 01.1.1.3.04 Lymphatic intrathoracic 01.1.1.3.05 Lymphatic extrathoracic 01.1.1.3.06 Pericardia 01.1.1.3.07 Spine 01.1.1.3.08 Bone/joints other than spine 01.1.1.3.09 Meningitis 01.1.1.3.10 CNS other than meningitis 01.1.1.3.11 Genito-urinary tract 01.1.1.3.12 Peritoneal/digestive 01.1.1.3.13 TB with poly-organ failure/ TB sepsis 01.1.2 other AIDS-defining infection 01.1.2.1 with lungs involvement 01.1.2.2 with CNS involvement 01.2.1 AIDS Malignancy localised to lungs 01.3 IRIS after cART initiation (can only be used as contributing cause of death) 02.1.2 Bacterial pneumonia 02.1.3 Bacterial meningitis 02.2.2 other pneumonia 02.2.3 other with CNS involvement 19.3.1 Toxicity to anti-TB drugs 01 AIDS (ongoing active disease) 01.1 Infection 01.2 Malignancy 02 Infection (other than 01.1) 02.1 Bacterial 02.1.1 Bacterial with sepsis 02.2 Others 02.2.1 Others with sepsis 02.3 Unknown aetiology 02.3.1 Unknown with sepsis 03 Chronic viral hepatitis (progression of/complication to) 03.1 HCV 03.1.1 HCV with cirrhosis 03.1.2 HCV with liver failure 03.1.3 HCV with liver cancer 03.2 HBV 03.2.1 HBV with cirrhosis 03.2.2 HBV with liver failure 03.2.3 HBV with liver cancer 04 Malignancy (other than 01.2 and 03, 03.1, 03.2) 04.03 ANUS - Anal cancer 04.04 BLAD - Bladder cancer 04.05 BONE - Bone cancer 04.06 BRAC - Brain cancer 04.07 BRCA - Breast cancer 04.10.1 ALL - Leukaemia: Acute lymphoid 04.10.2 AML - Leukaemia: Acute myeloid 04.10.3 CLL - Leukaemia: Chronic lymphoid 04.10.4 CML - Leukaemia: Chronic myeloid 04.10.9 LEUK - Leukaemia: unspecified 04.11 COTC - Connective tissue cancer 04.12 ESOP - Esophagus cancer 04.13 GALL - Gallbladder cancer 04.14 GYCA - Gynaecologic cancer 04.15 HDL - Hodgkin lymphoma 04.16 HENE - Head and neck (incl. face) cancers 04.17 KIDN - Kidney cancer 04.18 COLO - Colon cancer 04.19 LIPC - Lip cancer 04.20 LIVR - Liver cancer 04.21 LUNG - Lung cancer 04.22 MALM - Malignant melanoma 04.27 MULM - Multiple myeloma 04.29 PANC - Pancreas cancer 04.31 PENC - Penile cancer 04.32 PROS - Prostate cancer 04.33 RECT - Rectum cancer 04.34 STOM - Stomach cancer 04.35 TESE - Testicular seminoma 04.36 UTER - Uterus cancer 04.40.1 MEAC - Metastasis: of adenocarcinoma 04.40.2 MEOC - Metastasis: of other cancer type 04.40.3 MESC - Metastasis: of squamuos cell carcinoma 04.40.9 META - Metastasis: unspecified 04.90 OTH - Other Malignancy Type 04.99 UNKP - Unknown Malignancy Type 05 Diabetes Mellitus (complication to) 06 Pancreatitis 07 Lactic acidosis 08 MI or other ischemic heart disease 08.1 AMI 08.1.1 Definitive AMI (Dundee 1) 08.1.2 Possible AMI (Dundee 2/9) 08.2 Other ischemic heart disease 09 Stroke 10 Gastro-intestinal haemorrhage (if chosen, specify underlying cause) 11 Primary pulmonary hypertension 12 Lung embolus 13 Chronic obstructive lung disease 14 Liver failure (other than 03, 03.1, 03.2) 15 Renal failure 16 Accident or other violent death (not suicide) 17 Suicide 18 Euthenasia 19 Substrance abuse (active) 19.1 Chronic Alcohol abuse 19.2 Chronic intravenous drug-use 19.3 Acute intoxication 20 Haematological disease (other causes) 21 Endocrine disease (other causes) 22 Psychiatric disease (other causes) 22.1 Mental and behavioural disorders due to use of psychoactive substances (other than alcohol and intravenous opioids) 22.2 Schizophrenia, schizotypal and delusional Disorders 22.3 Mood /Affective disorders (Major depressive disorder, Bipolar disorder and other mood disorders) 22.4 Neurotic, stress-related and somatoform disorders (including anxiety disorders, phobias, OCD, stress reaction, dissociative disorders, somatoform disorders) 22.5 Behavioral syndromes associated with physiological disturbances and physical factors (including eating disorders, sleep disorders, sexual disorders) 22.90 Other psychiatric disorders 23 CNS disease (other causes) 23.1 Movement disorders (Parkinson’s disease; dystonias and Parkinson-like syndromes) 23.2 Degenerative disorders of the central nervous system (Alzheimer's disease; Creutzfeldt–Jakob disease and other degenerative diseases of nervous system) 23.3 Demyelinating diseases of the central nervous system (Multiple sclerosis, other demyelinating diseases) 23.4 Epilepsy (including localised and generalized epilepsy and epileptic syndromes) 23.5 Polyneuropathies (Guillain–Barré syndrome and other polyneuropathies/disorders of the peripheral nervous system) 23.6 Diseases of myoneural junction and muscle (Miastenia gravis and other myoneural disorders) 23.90 Other disorders of the nervous system 24 Heart or vascular (other causes) 25 Respiratory disease (other causes) 26 Digestive system disease (other causes) 27 Skin and motor system disease (other causes) 28 Urogential disease (other causes) 29 Obstetric complications 30 Congenital disorders 31 Symptoms caused by mitochondrial toxicity (other than 06, 07) 32 Bleeding (haemophilia) 33 Sudden infant death 33.1 Child abuse 90 Other causes 91 Unclassifiable causes 92 Unknown 92.1 Unknown, Competing risks 01.1.1 Tuberculosis 01.1.1.1 Pulmonary tuberculosis 01.1.1.2 Extrapulmonary TB 01.1.1.2.01 Pleura (isolated, without lungs involvement 01.1.1.2.02 Lymphatic intrathoracic (isolated, without lungs involvement) 01.1.1.2.03 Lymphatic extrathoracic 01.1.1.2.04 Pericardia 01.1.1.2.05 Spine 01.1.1.2.06 Bone/joints other than spine 01.1.1.2.07 Meningitis 01.1.1.2.08 CNS other than meningitis 01.1.1.2.09 Genito-urinary tract 01.1.1.2.10 Peritoneal/digestive 01.1.1.2.11 TB with poly-organ failure/ TB sepsis 01.1.1.3 Disseminated tuberculosis 01.1.1.3.01 Lungs 01.1.1.3.02 Miliary 01.1.1.3.03 Pleura 01.1.1.3.04 Lymphatic intrathoracic 01.1.1.3.05 Lymphatic extrathoracic 01.1.1.3.06 Pericardia 01.1.1.3.07 Spine 01.1.1.3.08 Bone/joints other than spine 01.1.1.3.09 Meningitis 01.1.1.3.10 CNS other than meningitis 01.1.1.3.11 Genito-urinary tract 01.1.1.3.12 Peritoneal/digestive 01.1.1.3.13 TB with poly-organ failure/ TB sepsis 01.1.2 other AIDS-defining infection 01.1.2.1 with lungs involvement 01.1.2.2 with CNS involvement 01.2.1 AIDS Malignancy localised to lungs 01.3 IRIS after cART initiation (can only be used as contributing cause of death) 02.1.2 Bacterial pneumonia 02.1.3 Bacterial meningitis 02.2.2 other pneumonia 02.2.3 other with CNS involvement 19.3.1 Toxicity to anti-TB drugs A10A Insulin or derivatives hereof A10B Oral antidiabetic agents A11CC vitamin D A14A Anabolic steroids/appetite stimulants B01AC Anti-platelets C-HYP Other anti-hypertensive agents [C02, C03, C04, C07, C08] C09 ACE inhibitors C10 Lipid lowering agents G02CA Tocolysis H02 Corticosteroids J01 Antibiotics J01AA08 Minocycline (MINOCIN) J01EA01 Trimethoprim (MONOTRIM, NOPIL) J01EC02 Sulfadiazine J01EE Cotrimoxazole - Comb. of sulfonamides and trimethoprim (BACTRIM, EUSAPRIM, NOPIL) J01EE01 Sulfamethoxazole and trimethoprim (Bactrim) J01EE03 Sulfametrole and trimethoprim - Cosoltrime (MADERAN) J01FA09 Clarithromycine (KLACID) J01FA10 Azithomycine (ZITHROMAX) J01FF01 Clindamycine (DALACIN) J01GA01 streptomycin J01GB06 Amikacine (AMIKINE) J01MA02 Ciprofloxacine (CIPROXINE, CILOXAN) J01MA12 Levofloxacin (TAVANIC) J01MA14 Moxifloxacin J01RA02 Cosoltrime (MADERAN) J02AA01 Amphotericin B (FUNGIZON) J02AB Imidazoles (DAKTARIN, NIZORAL, PEVARYL …) J02AB02 Ketoconazole J02AC01 Fluconazole (DIFLUCAN) J02AC02 Itraconazole (SPORANOX) J02AC03 Voriconazole J02AC04 Posaconazole J02AC05 Isavuconazole J02AX01 Flucytosine J02AX04 caspofungin J04AB02 Rifampin (RIMATICIN) J04AB04 Rifabutin (MYCOBUTIN) J04AB05 Rifapentine (Priftin) J04AC01 Isoniazide (RIMIFON) J04AK01 Pyrazinamide (PYRAZINAMID) J04AK02 Ethambutol (EMB, MYAMBUTOL) J04AM05 RIFATER J04BA01 Clofazimine (LAMPREN) J04BA02 Dapsone J05AB01 Aciclovir (ZIVORAX) J05AB04 Ribavirin J05AB06 Ganciclovir (CYMEVENE) J05AB09 Famciclovir J05AB11 Valaciclovir (VALTEX) J05AB12 Cidofovir (VISTIDE) J05AB15 Valganciclovir J05AD01 Foscarnet (FOSCAVIR) J05AE11 Telaprevir (INCIVEK, INCIVO) J05AE12 Boceprevir (VICTRELIS) J05AE13 Faldaprevir J05AE14 Simeprevir J05AE15 Asunaprevir J05AF08 Adefovir (PREVEON) J05AF10 Entecavir J05AF11 Telbivudine J05AF12 Clevudine J05AR-DAAS Daclatasvir/Asunaprevir J05AX GRAZ-ELB Grazoprevir/Elbasvir J05AX14 Daclatasvir J05AX15 Sofosbuvir J05AX16 Dasabuvir J05AX65 Ledipasvir/Sofosbuvir J05AX67 Ombitasvir, paritaprevir(ABT-450) and ritonavir J07BM0 HPV Vaccine J07BM01 HPV Vaccine (types 6, 11, 16, 18) J07BM02 HPV Vaccine (types 16, 18) J07BM03 HPV Vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58) L01AA01 Cyclophosphamide (ENDOXAN) L01AD02 CCNU (LOMUSTINE) L01AX04 Dacabazine (DTIC - Dome) L01BA01 Methotrexate L01CA01 Vinblastin (VELBE) L01CA02 Oncovin (VINCRISTINE) L01CB01 Etoposide (VEPESIDE, EXITOP 100) L01DB01 Doxorubicine, Adriamycine (DOXIL, CAELYX, ADRIBLASTIN) L01DC01 Bleomycine L01XB01 Procarbazine (NATULAN) L03AA02 G-CSF/Filgastrim (NEUPOGEN) L03AB Interferons L03AB-AL2 Peginterferon alfa-2a/alfa-2b (PEGINTRON, PEGASYS) L03AB10 Peginterferon alfa-2b (PEGINTRON) L03AB11 Peginterferon alfa-2a (PEGASYS) L03AC-IL2 Interleukin 2 (PROLEUKIN) M05BA bisphosphonate N03A Antiepileptics N05A Antipsychotics N05CD Benzodiazepine derivatives N05CF Benzodiazepine related drugs N06A Antidepressant N07BC Other drugs used in opioid dependence N07BC01 Buprenorphine N07BC02 Methadone N07BC03 Levacetylmethadol N07BC04 Lofexidine N07BC51 Buprenorphine, combinations P01AX06 Atovaquone (WELLVONE, MEPRONE) P01BA03 Primaquine P01BD01 Pyrimethamine (DARAPRIM) P01BD51 Pyrimethamine/Sulfadoxine (FANSIDAR) P01CX01 Pentamidine aerosol (PENTACARNET) V03AB15 Naloxone V03AF03 Folinate of calcium (LEUCOVORINE) 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 18 Unwanted weight changes 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (e.g. DAA's for HCV, antibiotics 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 1 Treatment failure (i.e. virological, immunological, and/or clinical failure 1.1 Virological failure 1.2 Partial virological failure 1.3 Immunological failure - CD4 drop 1.4 Clinical progression 1.5 Resistance (based on test result) 10 Hyperlactataemie/lactic acidosis 11 Bone toxicity 15 Social contra-indication 16 Contra-indication unspecified 16.8 Contra-indication expired 16.9 Contra-indication – other 17 MTCT regimen completed 2 Abnormal fat redistribution 3 Concern of cardiovascular disease 3.1 Dyslipidaemia 3.2 Cardiovascular disease 4 Hypersensitivity reaction (skin eruption etc.) 5 Toxicity, predominantly from abdomen/G-I tract 5.1 Toxicity - GI tract 5.2 Toxicity - Liver 5.3 Toxicity - Pancreas 6 Toxicity, predominantly from nervous system 6.1 Toxicity - peripheral neuropathy 6.2 Toxicity - neuropsychiatric 6.3 Toxicity - headache 7 Toxicity, predominantly from kidneys 70 Pregnancy - toxicity concerns (during pregnancy) 75 Pregnancy - switch to a more appropriate regimen for PMTCT 8 Toxicity, predominantly from endocrine system 8.1 Diabetes 88 Death 9 Haematological toxicity (anemia etc.) 90 Side effects - any of the above but unspecified 90.1 Comorbidity 91 Toxicity, not mentioned above 91.1 Toxicity, unspecified 92 Availability of more effective treatment (not specifically failure or side effect related) 92.1 Simplified treatment available 92.2 Treatment too complex 92.3 Drug interaction 92.31 Drug interaction - commencing TB/BCG treatment 92.32 Drug interaction - ended TB/BCG treatment 92.33 Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) 92.4 Protocol change 92.5 Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) 92.6 End of empiric treatment 92.9 Change in treatment not due to side-effects, failure, poor adherence or contra-indication 93 Structured Treatment Interruption (STI) 93.1 Structured Treatment Interruption (STI) - at high CD4 94 Patient's wish/decision, not specified above 94.1 Non-compliance 94.2 Defaulter 95 Physician's decision, not specified above 96 Pregnancy (see also more specific codes 70 and 75 96.1 Pregnancy intended 96.2 Pregnancy ended 97 Study treatment 97.1 Study treatment commenced 97.2 Study treatment completed 97.6 Drug not available 98 Other causes, not specified above 99 Unknown 10 White/Caucasian 20 Black 21 > Sub-Saharan African 22 > Caribbean 23 > African-American 24 > Other Black 30 Hispanic/Latino/Latin American 40 Asian 41 > Chinese 42 > Southeas Asia (e.g. Thai, Vietnamese, Philippino) 43 > Indian Subcontinent (Indian, Pakistani, Bangladeshi) 44 > Japanese 45 > Other asian 50 Indigenous people from Americas or Alaska Native 60 Indigenous people from other continents/locations 70 Other ethnic groups 71 > Maghrebian 72 > Middle East/Arabic 73 > Turkish 74 > Roma people/Gypsy (whichever is term is acceptable) 98 Prohibited (there are countries with legal restrictions to collect information on ethnicity) 99 Unknown xxyy(zz) Mixed race/ethnicity. Combine 2-digits numbers from above (e.g. 1020 for white+black) 1.1 Hydrocephalus 1.2 Microcephaly 1.3 Neural tube defects 1.4 Central Nervous System (CNS) - Other 2.1 Cleft lip and palate 2.2 Eye, Ear, Face and Neck - Other 3.1 Acyanotic defects (e.g., ASD, VSD, AV canal, PDA) 3.2 Cyanotic defects (e.g. Tetralogy of Fallot, transposition, pulmonary atresia, truncus, Ebstein's) 3.3 Heart - Other 4.1 Gastroschisis 4.2 Intestinal atresia 4.3 Tracheo-esophageal Fistula 4.4 Omphalocele 4.5 Anorectal malformation 4.6 Gastro-intestinal system - Other 5.1 Ambiguous genitalia 5.2 Ambiguous genitalia 5.3 Genitals - Other 6.1 Posterior urethral valves 6.2 Renal and urinary system - Other 7.1 Talipes equinovarus (club foot) 7.2 Limb defects – Other 8.1 Down syndrome 8.2 Chromosomal anomaly – Other 9.1 Other Organ System(s) Abnormality 9 Unknown A A A1 A1 A2 A2 A3 A3 B B B1 B1 B2 B2 B3 B3 C C C1 C1 C2 C2 C3 C3 N N 1 Employed as an employee 2 Self-employed / Family worker 3 Apprentice / trainee 4 Unemployed and actively seeking work 5 Student 6 Retired / Pre-retired 7 Engaged in family duties 8 Unable to work due to ill health 9 Other situation 99 Unknown 1 Indefinite duration 2 Fixed-term 3 Other 9 Unknown 0 None 1 primary education (ISCED97-1) 2 lower secondary (ISCED97-2) OR end of basic education 3 upper secondary or post-secondary non-tertiary (ISCED97 3 and 4) 4 university or post-graduate (ISCED97 5A and 5B) 8 other, only if none of the codes 0 to 4 applies 9 unknown